Fibrinolytic/Proteolytic Treatment of Myofacial and Neuropathic Pain and Related Conditions

Abstract

A method is disclosed to dissolve protein deposited in muscle. The method includes the step of administering an effective amount of an agent selected from the group consisting of fibrinolytics, proteolytics, photolytic and magnelytic agents.

1 . A method to dissolve protein deposited in muscle, said method comprising administering an effective amount of an agent selected from the group consisting of fibrinolytics, proteolytics, photolytic and magnelytic agents. 
     
     
         2 . A method according to  claim 1 , wherein the muscle is a skeletal muscle selected from the group consisting of the spine and the limbs, and wherein said agent alleviates pain. 
     
     
         3 . A method according to  claim 1  wherein the agent is a fibrinolytic. 
     
     
         4 . A method according to  claim 1  wherein the agent is a proteolytic. 
     
     
         5 . A method according to  claim 1  wherein the agent is a photolytic agent. 
     
     
         6 . A method according to  claim 1  wherein the agent is a magnelytic agent. 
     
     
         7 . A method according to  claim 1  wherein the agent is administered using a technique selected from the group consisting of topically, intravenously, orally, and mucosally. 
     
     
         8 . A method according to  claim 1  wherein the agent is administered via a route selected from the group consisting of rectal suppositories, nasal sprays, optic drops, topical formulations, vaginal compositions and intravenous composition. 
     
     
         9 . A method according to  claim 1  wherein the agent is administered via a rectal suppository. 
     
     
         10 . A method according to  claim 1  wherein the agent is administered via a route selected from the group consisting of nasal sprays and inhalers. 
     
     
         11 . A method according to  claim 1  wherein the agent is administered via optic drops. 
     
     
         12 . A method according to  claim 1  wherein the agent is administered via a vaginal composition. 
     
     
         13 . A method according to  claim 1  wherein the agent is administered via an intravenous composition. 
     
     
         14 . A method according to  claim 1 , wherein said fibrinolytic is administered at a concentration in the range of about 0.1 mg/ml to about 2 mg/ml in a physiologically acceptable solution. 
     
     
         15 . A method according to  claim 1  wherein the fibrinolytic agent is selected from the group consisting of Serrapeptase and Nattokinase. 
     
     
         16 . A method according  claim 15  wherein 5000 IU (international units) of Serrapeptase is administered is administered orally in the form of one to four tablets three times daily. 
     
     
         17 . A method according  claim 15  wherein 5000 IU of Nattokinase is administered orally in the form of one to four tablets three times daily. 
     
     
         18 . A method according to  claim 15 , wherein the agent is formulated to comprise, per 30 mls., a composition selected from the group consisting of serrapeptase 10-50,000 IU, nattokinase 10-50,000 IU, lipase 10-50,000 IU, Rutin 10-50,000 IU, amla 10-50,000 IU, other proteases, and fibrinolytics. 
     
     
         19 . A method according to  claim 8 , wherein,
 the agent is formulated for mucosal or vaginal or rectal administration;   the agent comprises a solution having the components mixed in a sterile solution of water producing a concentration of about 0.1% to 5%;   wherein stronger or weaker solutions may be used to reduce or enhance effects; and   wherein other mixing agents may be used to enhance absorption transdermally.   
     
     
         20 . A method according to  claim 1  wherein the agent is formulated for pulmonary and nasal administration wherein the agent is—delivered by a lung and nasal vaporizer inhaler (respectively) in a metered dosing mechanism. 
     
     
         21 . A method according to  claim 10  wherein the inhaler contains a composition selected from the group consisting of serrapeptase 10-50,000 IU, nattokinase 10-50,000 IU, lipase 10-50,000 IU, Rutin 10-50,000 IU amla 10-50,000 IU; other proteases, and mixtures thereof. 
     
     
         22 . A method according to  claim 1  wherein the agent is formulated for veterinary use. 
     
     
         23 . A method according to  claim 22  to treat consumable animal meat, said method comprising administering an effective amount of the agent to dissolve protein deposited in skeletal muscles, organs or tissues of farm animals to improve or increase perceived improved quality of farm animal products and/or quality of life.